MDT-AP-1138
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 21.96
- os_event
- true
- age_years
- 2
- sex
- M
- new_clusters
- C3
- umap1_2d
- 6.198159175
- umap2_2d
- 3.680615352
- umap1_3d
- 2.944852843
- umap2_3d
- -2.62452493
- umap3_3d
- -2.582805864
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.410
- WNT_BETA_CATENIN_SIGNALING+0.370
- MYC_TARGETS_V2+0.230
- G2M_CHECKPOINT+0.170
- DNA_REPAIR+0.160
- HEME_METABOLISM+0.150
- E2F_TARGETS+0.070
- PI3K_AKT_MTOR_SIGNALING+0.030
- ADIPOGENESIS+0.010
- PROTEIN_SECRETION+0.010
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.510
- INTERFERON_ALPHA_RESPONSE-0.510
- INFLAMMATORY_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.470
- TNFA_SIGNALING_VIA_NFKB-0.440
- IL6_JAK_STAT3_SIGNALING-0.430
- KRAS_SIGNALING_UP-0.410
- COMPLEMENT-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- COAGULATION-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0038 | Med | Medulloblastoma | 0.910 |
| 2 | 20040095.TNBC | — | E | 0.903 |
| 3 | MDT-AP-0396 | Med | Medulloblastoma | 0.902 |
| 4 | MDT-AP-0578 | Med | Medulloblastoma | 0.892 |
| 5 | MDT-AP-0715 | Med | Medulloblastoma | 0.889 |
| 6 | 88306 | EPN | Supratentorial EPN | 0.884 |
| 7 | SJEPD031175_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.884 |
| 8 | MDT-AP-0350 | Med | Medulloblastoma | 0.882 |
| 9 | ERR2208948 | — | — | 0.882 |
| 10 | MDT-AP-0574 | Med | Medulloblastoma | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.410 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.070 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.010 | Remibrutinib | — uncovered |